SCHEMBL5450136

SCHEMBL5450136

CCCCC1CCN(CCCn2cc(C(C)=O)c3cccc(Cl)c32)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.48
CHRM1 P11229 4/20 0.48
CHRM2 P08172 3/20 0.48
CHRM4 P08173 3/20 0.48
CHRM5 P08912 3/20 0.48
CHRM3 P20309 3/20 0.48
DRD4 P21917 3/20 0.48
ADRA1D P25100 2/20 0.48
ADRA1A P35348 2/20 0.48
ADRA1B P35368 2/20 0.48
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
ADRA2B P18089 1/20 0.48
HRH1 P35367 1/20 0.48
PRPS1 P60891 1/20 0.46
CNR1 P21554 2/20 0.46
CNR2 P34972 4/20 0.43
DRD3 P35462 4/20 0.42
ADRB2 P07550 1/20 0.42
ADRB1 P08588 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14464351 0.95 PRPS1 (0.47) DRD2CHRM1CHRM2CHRM4CHRM5
SCHEMBL5460362 0.89 CHRM1 (0.56) DRD2CHRM1CHRM2CHRM4CHRM5
SCHEMBL5462009 0.88 CHRM1 (0.48) DRD2CHRM1CHRM2CHRM4CHRM5
SCHEMBL14410946 0.87 CNR2 (0.54) DRD2CHRM1CHRM2CHRM4CHRM5
SCHEMBL5444433 0.85 HRH3 (0.46) PRPS1HRH3ALDH1A1
SCHEMBL5335371 0.84 CHRM1 (0.53) DRD2CHRM1CHRM2CHRM4CHRM5
SCHEMBL5450982 0.83 PRPS1 (0.45) DRD4PRPS1CNR1CNR2ALDH1A1
SCHEMBL5453762 0.82 KCNH2 (0.53) PRPS1CNR1CYP2D6
SCHEMBL5449236 0.82 PRPS1 (0.44) PRPS1CNR1CNR2
SCHEMBL14411139 0.82 PRPS1 (0.44) PRPS1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF GIPR, GHSR, GHRHR DRD2 2688/4885CHRM1 1153/4885CHRM2 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.